Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kineret in COVID-19 Pneumonia (CORIMUNO-ANA)
NCT04341584Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2020
- Primary completion
- May 2020
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of anakinra in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Percentage of Participants With Non-invasive Ventilation, Mechanical Ventilation or Death at Day 14, Percentage of Participants With WHO Clinical Progression Scale > 5 at Day 4 and 2 more. Started Apr 2020; status: completed.
02
Drugs
anakinra
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04341584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04341584.